Gastric ulcer: a double blind comparison of 800 mcg misoprostol versus 300 mg ranitidine.
Seventy-nine patients with endoscopically confirmed gastric ulcers received either ranitidine (37 patients) or misoprostol (42 patients) in a randomized double-blind manner. Fifty-six percent of the patients treated with ranitidine, and 38% of those treated with misoprostol presented with endoscopically healed ulcers after four weeks of treatment. After eight weeks complete healing had occurred in 86% of the patients receiving ranitidine, and 74% of those on misoprostol. These differences were not statistically significant. In smokers, ranitidine was superior to misoprostol, leading to a higher healing rate at four weeks (73% versus 20%). Thus there was no evidence that in patients with gastric ulcer misoprostol overcomes the negative effect of cigarette smoking.
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016595:Misoprostol; D011897:Random Allocation; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D012907:Smoking / Q000009:adverse effects; D013276:Stomach Ulcer / Q000188:drug therapy*
D016595:Misoprostol; D011899:Ranitidine; D000527:Alprostadil